These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

99 related articles for article (PubMed ID: 23418364)

  • 1. Provincial drug plan officials' views of the Canadian drug safety system.
    Lexchin J; Wiktorowicz M; Moscou K; Eggertson L
    J Health Polit Policy Law; 2013 Jun; 38(3):545-71. PubMed ID: 23418364
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmaceutical policies in Canada: another example of federal-provincial discord.
    Anis AH
    CMAJ; 2000 Feb; 162(4):523-6. PubMed ID: 10701389
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Risk management frameworks for human health and environmental risks.
    Jardine C; Hrudey S; Shortreed J; Craig L; Krewski D; Furgal C; McColl S
    J Toxicol Environ Health B Crit Rev; 2003; 6(6):569-720. PubMed ID: 14698953
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inter-provincial inequality of public health services in China: the perspective of local officials' behavior.
    Chen T; Wang Y; Luo X; Rao Y; Hua L
    Int J Equity Health; 2018 Jul; 17(1):108. PubMed ID: 30064429
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inter-jurisdictional cooperation on pharmaceutical product listing agreements: views from Canadian provinces.
    Morgan SG; Thomson PA; Daw JR; Friesen MK
    BMC Health Serv Res; 2013 Jan; 13():34. PubMed ID: 23363626
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Canadian policy makers' views on pharmaceutical reimbursement contracts involving confidential discounts from drug manufacturers.
    Morgan SG; Thomson PA; Daw JR; Friesen MK
    Health Policy; 2013 Oct; 112(3):248-54. PubMed ID: 23809914
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Do provincial drug benefit initiatives create an effective policy lab? The evidence from Canada.
    Pomey MP; Morgan S; Church J; Forest PG; Lavis JN; McIntosh T; Smith N; Petrela J; Martin E; Dobson S
    J Health Polit Policy Law; 2010 Oct; 35(5):705-42. PubMed ID: 21123668
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inter-provincial variation in government drug formularies.
    Grégoire JP; MacNeil P; Skilton K; Moisan J; Menon D; Jacobs P; McKenzie E; Ferguson B
    Can J Public Health; 2001; 92(4):307-12. PubMed ID: 11962119
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Introduction of direct-to-consumer advertising of prescription drugs in Canada: an opinion survey on regulatory policy.
    Mintzes B; Barer M; Lexchin J; Bassett KL
    Res Social Adm Pharm; 2005 Jun; 1(2):310-30. PubMed ID: 17138480
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Canadian health care system: past, present, and future.
    Stolberg HO
    J Am Coll Radiol; 2004 Sep; 1(9):659-70. PubMed ID: 17411676
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Canada Pension Plan's experience with investing its portfolio in equities.
    Sarney M; Preneta AM
    Soc Secur Bull; 2001-2002; 64(2):46-56. PubMed ID: 12428509
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Beneficiary cost sharing under Canadian provincial prescription drug benefit programs: history and assessment.
    Grootendorst P
    Can J Clin Pharmacol; 2002; 9(2):79-99. PubMed ID: 12172588
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Harmonization of HTA--based reimbursement and regulatory approval activities: a qualitative study.
    Tsoi B; O'Reilly D; Masucci L; Drummond M; Goeree R
    J Popul Ther Clin Pharmacol; 2015; 22(1):e78-89. PubMed ID: 25715384
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Gateway Paper--proposed health reforms in Pakistan--interface considerations.
    Nishtar S
    J Pak Med Assoc; 2006 Dec; 56(12 Suppl 4):S78-93. PubMed ID: 17595835
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The nature and scope of gambling in Canada.
    Smith G
    Addiction; 2014 May; 109(5):706-10. PubMed ID: 23651388
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Need for an improved submission process for listing drugs for reimbursement in Canadian provinces.
    West R; Borden EK; Collet JP; Rawson NS; Tonks RS
    Can J Clin Pharmacol; 2003; 10(4):207-10. PubMed ID: 14712327
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Why home birth? A qualitative study exploring women's decision making about place of birth in two Canadian provinces.
    Murray-Davis B; McNiven P; McDonald H; Malott A; Elarar L; Hutton E
    Midwifery; 2012 Oct; 28(5):576-81. PubMed ID: 22889685
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Emergent patterns in the regulation of pharmaceuticals: institutions and interests in the United States, Canada, Britain, and France.
    Wiktorowicz ME
    J Health Polit Policy Law; 2003 Aug; 28(4):615-58. PubMed ID: 12956518
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Shaking up the status quo: how AIDS activists have challenged drug development and approval procedures.
    Dunbar MM
    Food Drug Cosmet Law J; 1991 Sep; 46(5):673-706. PubMed ID: 11651380
    [No Abstract]   [Full Text] [Related]  

  • 20. Cost shifting and timeliness of drug formulary decisions in atlantic Canada.
    Scobie AC; Mackinnon NJ
    Healthc Policy; 2010 Feb; 5(3):100-14. PubMed ID: 21286272
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.